Compare Global X MSCI Argentina ETF (ARGT) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X MSCI Argentina ETF vs 22nd Century Group Inc — how do they compare? Global X MSCI Argentina ETF trades at $94.9, while 22nd Century Group Inc trades at $4.11 (market cap $1.46M). Which is the better fit depends on your goals.
| ARGT | XXII | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $102.94 | $1.85K |
52-Week Low | $67.55 | $3.90 |
Market Cap | — | $1.46M |
Enterprise Value | — | -$6.77M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARGT (Global X MSCI Argentina ETF) trades at $95.07, up 3.08% with a neutral technical signal. The ETF shows bullish moving averages but mixed oscillators, with support at $92 and resistance at $93. Recent positive sentiment stems from Argentina's economic reforms under the Milei Administration, with Seeking Alpha upgrading the rating to buy citing 28% upside potential based on valuation re-rating opportunities.
The outlook appears constructive given Argentina's improving macroeconomic backdrop, though concentration risk in MercadoLibre and ongoing economic transition pose challenges. Wall Street sentiment has turned positive with institutional accumulation noted, but investors should monitor fiscal stabilization progress and inflation trends for sustained momentum.
XXII trades at $4.23, down 2.08% on the day, amid a bearish technical signal. The company's financials show deep losses with a net income margin of -65.76% and negative ROE of -130.19% for 2026. Recent news highlights expansion of its VLN reduced-nicotine cigarettes in California and New York, aiming to capture market share. Analyst consensus is 75% buy, but earnings misses in Q4 2025 and Q1 2026 raise execution concerns.
The outlook hinges on VLN's commercial success and FDA regulatory pathway. High cash burn necessitates ongoing financing, evident in 2026's $17M financing inflow. Risks include persistent unprofitability, competitive pressures, and reliance on tobacco harm reduction narrative. Upside depends on revenue scaling and margin improvement from new retail launches.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X MSCI Argentina ETF
ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.
Read more on ARGT →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
